We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Another inhaled insulin casualty.
- Authors
Aldridge, Susan
- Abstract
The article reports on the cancellation of the development of the phase 3 inhaled insulin program by the Novo Nordisk of Bagsvaerd in Denmark. According to the author, the Danish group has stated that their is no point on spending development to be the third-place product in a niche market. He added that the device which uses Aradigm's AERx liquid aerosol system has offered no benefit over other pen devices including the FlexPen of Novo. Moreover, the AIR insulin of Lilly which is on phase 3 is produced with Cambridge, Massachusetts biotech Alkermes.
- Subjects
DENMARK; BIOTECHNOLOGY; CHEMICAL engineering; HYPOGLYCEMIC agents; PANCREATIC secretions; INSULIN; HORMONES; NOVO Nordisk A/S; ARADIGM Corp.
- Publication
Nature Biotechnology, 2008, Vol 26, Issue 3, p255
- ISSN
1087-0156
- Publication type
Article
- DOI
10.1038/nbt0308-255a